Adenocarcinoma
Conditions
Keywords
prostate cancer, lung cancer, pancreatic cancer, colorectal cancer, bladder cancer
Brief summary
A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.
Interventions
DRUGImmunotherapeutic Agents
Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
DEVICEAblation
Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
Sponsors
Gary Onik MD
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Treatment with the MyVaccx System * Greater than 18 years of age * Signature of the informed consent
Exclusion criteria
* 2 subjects treated with the MyVaccx System with known visceral disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MyVaccx immunotherapy treatment impact on late stage cancer disease | From date of treatment until the date of death from any cause up to 60 months | Time to death after the start of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MyVaccx immunotherapy treatment impact on late stage cancer disease | Time to progression after a complete or partial response up to 60 months | Complete and partial response to treatment based on the iRESIST criteria |
Countries
United States
Outcome results
None listed